Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Merck Sharp & Dohme Corp. v. Xellia Pharmaceuticals ApS
Case Number:
1:14-cv-00199
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
July 01, 2015
Xellia Found To Infringe Merck Anti-Fungal Med Patent
Xellia Pharmaceuticals ApS' generic version of the anti-fungal medication Cancidas infringes on one of the patents held by Merck Sharp & Dohme Corp., a Delaware federal judge ruled on Tuesday.
-
February 18, 2014
Merck Sues Xellia Over Plan For Generic Anti-Fungal Drug
Merck Sharp & Dohme Corp. targeted drug manufacturer Xellia Pharmaceuticals ApS with a lawsuit in Delaware federal court on Friday, alleging that the generics company's proposed version of the anti-fungal medication Cancidas will infringe on one of Merck's patents.